Introduction
Overexpression of the epidermal growth factor (EGF) receptor (HER1) and/or the closely related c-erbB2 receptor (HER2) is observed in a number of tumors and is correlated with an unfavorable prognosis, altered response to chemotherapy, and decreased survival (Slamon et al., 1987 (Slamon et al., , 1989 Hynes, 1993; Gabrilove and Mendelsohn, 1990; Wosikowski et al., 1997; Pegram et al., 1998; Thor et al., 1998; Ross and Fletcher, 1998) . Therefore, receptor blockade and/or inhibition are treatment strategies that may inhibit tumor growth and malignant potential. Early clinical success using the anti-HER2 and anti-HER1 antibodies has encouraged the development of small molecular agents that target these receptors with greater ecacy and speci®city (Levitzki and Gazit, 1995; Klohs et al., 1997; Fan and Mendelsohn, 1998; Fry et al., 1998; Gibbs, 2000) . Although clinical trials using anti-HER1 or anti-HER2 antibodies indicate that tumor responses are achieved principally in patients whose tumors have high receptor levels (Ross and Fletcher, 1999) , a signi®cant subset of these patients have tumors that are refractory to treatment. The mechanism(s) of resistance to these HER1/HER2 inhibitory compounds remains unclear.
EGF binds HER1 and activates its tyrosine kinase activity. This results in activation of mitogen-activated protein kinase (MAPK) pathways. HER1 signals principally through the Ras-Raf-MEK-ERK pathway known as a classical MAPK pathway. Activation of MAPK culminates in the induction of cyclin D1, which serves as a sensor of growth factors, and often in the simultaneous induction of p21 which can either activate or inhibit cyclin-dependent kinases (Sherr and Roberts, 1999; Sherr, 2000) .
The basis for dierential sensitivity of cancer cells to HER1/HER2 inhibitors is unknown. Possibilities include dierences at the level of receptor activation, MAPK pathway activation, and downstream eectors such as p21 and cyclin D1. Finally, they may include the physiological relevance of receptor signaling in cancer cells. In normal cells, growth factors are necessary to initiate and maintain the transition through G1 phase leading to S phase. The point in G1 at which commitment occurs and the cell no longer requires growth factors to complete the cell cycle has been termed the restriction point (Blagosklonny and Pardee, 2001 ). Cancer cells may be independent from growth factors due to activation of pathways downstream of the restriction point.
Reliance on the EGF growth factor receptor pathway in cancer cells and amongst the 60 NCI Drug Screen cell lines is not fully understood. Hence, we set out to ascertain potential dierences amongst sensitive and insensitive cell lines by initially examining mechanisms related to receptor activation and signaling, followed by studying the physiologic consequences of EGF receptor activation or inhibition in representative cell lines.
To examine the question of dierential sensitivity, we have evaluated drugs which interrupt HER1 and HER2 signaling, including several belonging to the quinazoline class of compounds (Fry et al., 1998) . These drugs are small molecules that are potent HER1 and HER2 inhibitors. They are known to interact with the receptor's ATP binding site, thereby inhibiting the kinase domain essential to transduce ligand-induced signaling (Fry et al., 1998) . Using these and other receptor kinase inhibitors, we sought to de®ne a cellular model to explore the molecular basis for the dierential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Results

Correlations of effects of HER1 inhibitors and expression of HER1, HER2, and TGF-a
We wanted to examine the hypothesis that HER1/ HER2 speci®c inhibitor potency relates to the HER1/ HER2 expression of a cancer cell. Within the NCI Drug Screen, 60 cell lines are currently being phenotyped and catalogued according to their molecular composition . For each cell line, HER1 and HER2 levels have previously been quantitated (Wosikowski et al., 1997) . Using this data, it is possible to correlate the growth inhibition due to speci®c compounds with the level of receptor mRNA expression. Using other drugs and molecular targets, similar analyses have been shown to be reliable for the identi®cation of biologic interactions between a drug and molecular targets .
Previously, 22 tyrosine kinase inhibitors were submitted to the drug screen and cytotoxicity pro®les were generated. Eleven of the 22 inhibitors were known a priori to be potent inhibitors of HER1 and HER2 kinase activity (Bridges et al., 1996; Fry et al., 1998) . AG1478, , is the prototype for this class of compounds and is commonly used as a potent and selective inhibitor of HER1 in laboratory models. The clinical lead compound, PD183805, is an irreversible inhibitor that aects all members of the EGF family of receptors (Levitzki and Gazit, 1995; Fry et al., 1998) . The remaining compounds were known to be potent inhibitors of other non-HER1/HER2 tyrosine kinases.
To test the hypothesis that HER1/HER2 speci®c inhibitors are most eective in HER1/HER2-expressing cell lines, Pearson correlation coecients (PCC) were obtained for the cytotoxicity pro®le of each compound relative to the level of expression for HER1, HER2, and TGF-a in each of the 60 cell lines within the NCI Drug Screen. A previous study had identi®ed two of these compounds as being correlated (PD153035 and PD153717) with EGF receptor expression (Wosikowski et al., 1997) . Similarly, the cytotoxicity pro®les for the prototype AG1478 could be compared to pro®les of the other kinase inhibitors. High Pearson correlation coecients (PCC) values would indicate similar cytotoxicity patterns. Correlative values for HER1, HER2, and TGF-a were positive if cell lines with high levels were growth inhibited by the drug at low concentrations. In this data set, negative correlative values were indicative of a reciprocal relationship. Table 1 shows Pearson correlation coecients for AG1478, HER1, HER2, and TGF-a. Compounds known to have speci®c HER1 and HER2 activity had similar patterns of cytotoxicity to that of AG1478 (median correlation=0.664, range 0.381 ± 1.0), whereas non-HER1/HER2 speci®c inhibitors were signi®cantly dierent (median correlation=0.259, range 0.128 ± 0.340). We conclude from these studies that sucient similarities exist amongst the 11 HER1/HER2 tyrosine kinase inhibitors to justify grouping them in subsequent analyses using the NCI Drug Screen database. Grouping these drugs can add strength to subsequent analyses as individual drug eects on cell lines can be diluted and common growth inhibitory pathways can be highlighted.
The correlation coecients for HER1, HER2, and TGF-a were highest amongst the 11 drugs known to be speci®c inhibitors of kinase activity for these receptors, with the most signi®cant dierences evident for HER2 and TGF-a expression (median 0.257 vs 70.026, and 0.343 vs 0.191, respectively).
Although activities of speci®c inhibitors strongly correlated with each other, their correlations with HER1 levels were surprisingly weak. This could indicate that either these compounds are active in cell lines lacking HER1 or that a subset of call lines with high HER1 expression is insensitive to these inhibitors.
Activity pattern for 11 known HER1/HER2 specific kinase inhibitors amongst the NCI Drug Screen cell lines
To address this question, the average 50% growth inhibition (GI50) for the 11 HER1/HER2 speci®c compounds was calculated for each of the 60 cell lines within the NCI Drug Screen. These values were subsequently plotted against the HER1 expression for each cell line to identify the pattern of sensitivity of Within Group 1, 13 cell lines had low HER1 expression (55 units) and were relatively insensitive to the inhibitors (median GI50 7.76 mM, range: 5.33 ± 14.01 mM). Ten cell lines formed Group 2. These cell lines had high HER1 expression (median 835 units, range: 59, 2141 units) and as expected displayed greater sensitivity to the inhibitors (median GI50 0.58 mM, range: 0.07 ± 1.42). However, 33 cell lines formed Group 3. These cell lines had high HER1 expression (median 373 units, range: 17 ± 3767 units), but were relatively insensitive to the inhibitors (median GI50 7.42 mM, range: 3.01 ± 16.06 mM). In the latter two groups, HER1 expression was similar; however, a greater than 10-fold dierence in GI50 for the speci®c inhibitors was evident with some as great as 1000-fold.
We conclude that high levels of HER1 expression are necessary but not sucient for the sensitivity to HER1/ HER2 inhibitors. A majority of cell lines are insensitive to HER1/HER2 inhibitors despite high levels of HER1 expression. The simplest explanation of the resistance is that these compounds do not inhibit HER1 signaling in the resistant cell lines. Ten representative tyrosine kinase sensitive (EKVX, DU145, SNB-75, OVCAR-3, and UO-31) and insensitive (A549, PC-3, SF295, OVCAR-4, and NIH/ADR-RES) HER1 overexpressing cell lines ( Figure 1b ) were treated with EGF in the absence or presence of AG1478. Phosphorylation of HER1 and MAP kinase as determinants of early EGF-activated receptor signaling events was determined by immunoblot assays (Figure 2 ). Following a 10 min stimulation with 30 ng/ml EGF, cells that were normally proliferating in complete media had an appropriate increase in HER1 and MAP kinase phosphorylation, indicating appropriate EGF-mediated receptor activation and early signaling response associated with cell proliferation. This eect was inhibited with 1 mM AG1478 in both sensitive and insensitive cell lines. Interestingly, this concentration of AG1478 is sucient to cause growth inhibition in sensitive cell lines, whereas insensitive cell lines require 10 mM or greater for similar eects. These results indicate an uncoupling between HER1/MAP kinase inhibition and growth inhibition in insensitive cell lines. Hence, if dierences in signaling exists, they are likely to be downstream to MAPK and not at the level of early signaling events mediated by the receptor. Alternatively, the proliferative signaling cascade mediated by HER1/MAPK is not the only pathway essential to cancer cells and dierences in other pathways may explain the dierential sensitivity. While dierential sensitivity of cancer cells to HER1/ HER2 speci®c inhibitors could be attributed to a dierence in the physiologic importance of receptor signaling, our studies do not exclude variable induction of cell cycle checkpoint inhibitors. Previous reports have linked p21 to the MAPK pathway (Zeng and ElDeiry, 1996) . Therefore, induction of the cell cycle inhibitor p21 was assessed following EGF and AG1478 treatment (Figure 3 ). We found that AG1478 treatment resulted in variable induction in both sensitive and insensitive cell lines. Instead, EGF stimulation of cells induced p21 in most of the cell lines. This indicates that EGF signaling is intact downstream at the level of p21, but also that p21 induction does not determine the dierential antiproliferative response. Similarly, EGF and AG1478 were able to induce cyclin D1 in druginsensitive and sensitive cell lines with low basal levels of cyclin D1 but no correlation between cyclin D1 and the sensitivity to HER1 inhibitors was found (data not shown).
Other regulators that act upstream of the restriction point were investigated. The expression and functional status of these proteins in sensitive and insensitive cell lines was obtained from the NCI Drug Screen Table 2 shows the Ras, Raf-1, p53, Mdm2, and p21 data for representative cell lines. No dierences between the cell line groups were evident. The absence of dierences in molecular phenotypes suggests that signaling through the involved pathways is intact in sensitive and insensitive cell lines. Therefore, we conclude that proliferation signals upstream of p21 and cyclin D1 cannot explain the dierential sensitivity to HER1/HER2 inhibitors.
HER1/HER2 specific inhibitors mediate a G1 growth arrest in EGF-responsive cells Already shown in the above studies are intact HER1-MAPK responses to growth factor in sensitive and insensitive cell lines indicating the presence of functional early proliferative signaling cascades (signals preceding the restriction point of the cell cycle) in both cell line groups. To explore potential downstream signal transduction dierences in sensitive and insensitive cell lines and to address the biologic relevance of the receptor activation, cell cycle analysis was performed on representative ®ve sensitive and ®ve insensitive cell lines following exposure to 1 mM AG1478 (Table 3 and Figure 4 ). This AG1478 concentration was shown to fully inhibit HER1 signaling. None of the ®ve insensitive cell lines displayed any indication of G1 growth arrest. In contrast, in sensitive cell lines, there was a decrease in the S fraction and in two out of ®ve also an increase in the G1 fraction indicating that AG1478 mediated a G1 phase arrest.
Next, we asked whether the insensitive cells were responsive to activation of HER1 by EGF. EGF responsiveness in inhibitor sensitive and insensitive cell lines was assessed by DNA cell cycle analysis (Table 3 and Figure 4 ). Exogenous EGF should augment a cell's proliferative capacity if that receptor and downstream signaling pathway are Figure 2 Eect of EGF and AG1478 on phosphorylation of HER1 and MAP kinase in sensitive and insensitive cell lines. Equal amounts of protein were separated by SDS ± PAGE electrophoresis and immunoblots were obtained for phosphorylated HER1 and ERK2 (MAPK) proteins. EGF stimulation of receptor resulted in HER1 and ERK2 phosphorylation indicating normal early signaling events in sensitive and insensitive cell lines. This eect was abrogated by 1 mM AG1478 in all cell lines Figure 3 Eects of EGF and AG1478 on p21 expression in sensitive and insensitive cell lines. Cells were treated with either 30 ng/ml EGF, 1 mM AG1478, or left untreated (control). p21 was measured by immunoblot as described in Materials and methods
Oncogene
Differential sensitivity of cancer cells to HER1/HER2 inhibitors PC Bishop et al functional. Hence, cells treated for 24 h with 30 ng/ mL exogenous EGF were harvested, and stained with propidium iodide for¯ow cytometry analysis. Five of ®ve cell lines with high levels of HER1 and sensitivity to receptor inhibitors exhibited an increase in S phase fraction. Only one of ®ve HER1/HER2 inhibitor insensitive lines responded to EGF with an increase in the S fraction of the cell cycle. These results indicate that cells which are insensitive to HER1/HER2 inhibitors are also unresponsive to EGF. Taken together with the studies that showed that HER1 and MAP kinase from EGF signaling were inhibited with 1 mM AG1478, these data are consistent with the notion that HER1 signaling is important for growth in AG1478 sensitive cells while it does not function as a proliferative factor in insensitive cells. This dispensibility of EGF signaling may represent autonomicity of cancer cells (Darzynkiewicz, 1995) .
Sensitivity to HER1/HER2 inhibitors in MCF-10 cells
Previously we demonstrated that MCF-10A, an EGFdependent immortalized mammary epithelial cell line, is very sensitive to AG1478 (Blagosklonny et al., 2000) . In contrast, the autonomic breast cancer cell line MCF7 was resistant to AG1478. Here, GI50, concentrations which inhibit growth by 50%, were calculated for ®ve compounds (Table 4) . Marked sensitivity to the tyrosine kinase inhibitors was evident in MCF-10A, whereas MCF7 cells were resistant. These results support the notion that EGF-dependent cells respond by growth arrest to inhibition of HER1 signaling.
Discussion
Clinical responses to the HER1 inhibitors and HER2/ neu inhibitors correlate with high levels of receptor expression. However, a signi®cant subset of patients with high receptor levels appear to be refractory to treatment. Dierential sensitivity to HER1 and HER2 targeting agents despite high levels of receptor 
Representative HER1/HER2 inhibitors sensitive and insensitive cell lines were grown in the presence of normal growth media with 1 mM AG1478, or 30 ng/ml exogenous EGF for 24 h. Cell cycle analysis results are displayed relative to normal growth conditions without the addition of drug or exogenous growth factor and expressed as a change from normal growth baseline: =no change; arrow (510% decrease or increase, respectively) expression is a major hindrance to the success of these agents (Bishop et al., 1999) . Representative of this clinical problem, we characterized a cellular model to study the complex intracellular signaling events in response to HER1 and HER2 inhibitors. The EGF receptor family initiates multiple intracellular signaling events leading to the activation of MAP kinases and cyclin dependent kinases which drive cell cycle progression (Gabrilove and Mendelsohn, 1990; Weinstein-Oppenheimer et al., 2000) . Deregulation of cellular growth can occur through receptor overexpression, activation in the MAP kinase pathway, and/or the activation of downstream oncogenes such as c-Myc (Hanahan and Weinberg, 2000; Sherr, 2000) . Since p53 may control response to activated oncogenes, loss of p53 may contribute to uncontrolled proliferation (Lowe et al., 1994; de Stanchina et al., 1998; Oren, 1999) . In our study, cell sensitivity to HER1 inhibitors was independent of p53 status.
Our studies demonstrate that discernable biological dierences exist amongst HER1/HER2 inhibitor sensitive and insensitive cells. Yet, low concentrations of HER1 inhibitors abrogated EGF receptor and MAPK activation in all cell lines, and no dierences between sensitive and insensitive cell lines were detected in the ability of the EGF pathway to regulate p21 and cyclin D1.
However, insensitive cells appear to have an unaected growth pattern following exogenous growth factor stimulation while sensitive cells are more likely to have a cell cycle response. Accordingly, despite the potent and eective functional inhibition of HER1 and MAPK by low inhibitor concentrations, little to no drug eect on growth can be demonstrated in insensitive cells. These studies argue that dierences in signaling downstream of HER1 and MAPK, or the existence and activity of pathways other than HER1, could confer a growth advantage in the insensitive cells. The sustained growth in cancer cells apparently requires downstream mutations that could interfere with the ability of HER1/HER2 inhibitors to control neoplastic cell growth. As such, the inability to predict responses to inhibitors by a mere evaluation of receptor expression level may be due to mutations downstream of the receptor and/or the expression of other dominant signaling pathways. A corollary to these observations is that HER1/HER2 directed therapy is likely to have little eect on cancers with activated downstream oncogenes or co-dominant alternative signaling pathways. In contrast, EGF-dependent immortalized cells were very sensitive to a panel of HER1 inhibitors. In agreement, a recent report demonstrated that pharmacological inhibition of intestinal EGF receptor induced lesions in normal mucosa in mice but failed to aect tumor growth (Ritland et al., 2000) . As various molecular databases become more comprehensive, it is likely that molecular dierences between sensitive and insensitive cells will emerge. 
Materials and methods
Materials
Drugs AG1478, [4-(3-Chloroanilino)-6,7-dimethoxyquinazoline] is a potent and selective inhibitor of epidermal growth factor receptor (Levitzki and Gazit, 1995) . PD 183805, PD 168393, PD 169541, PD 169540, and PD 174265 were obtained from Parke-Davis Pharmaceutical (Fry et al., 1998) . These compounds are receptor tyrosine kinase inhibitors with similar activity to AG1478. All pharmacological agents were solubilized in DMS to a ®nal stock solution concentration of 10 mM.
Cell lines
The NCI anticancer drug screen was the primary source of most cell lines used for analysis (Monks et al., 1991; Stinson et al., 1992 (Soule et al., 1990) were provided by David Salomon (NCI, Bethesda, MD, USA) and were cultured in Dulbecco's minimal essential medium (DMEM) ± Ham's F12 (1 : 1) medium containing 5% horse serum, 100 U/mL penicillin, and 100 mg/mL streptomycin (all from Bio¯uids Inc.) plus 20 mM HEPES, 4 mg/mL insulin, 500 ng/mL hydrocortisone, and 20 ng/mL EGF (all from Collaborative Biomedical Products, Bedford, MA, USA).
Cytotoxicity assays
Cytotoxicity assays adapted from those performed by the NCI drug Screen have previously been described (Wosikowski et al., 1997) . Brie¯y, 5000 to 40 000 cells are plated in 96-well microtiter plates according to predetermined growth characteristics and optimal plating densities for the respective cell lines. Inoculates were incubated for a period of 24 h at 378C for stabilization. Dilutions at twice the intended test concentration were subsequently added at time zero in 100-mL aliquots to the microtiter plate wells. Test compounds were usually evaluated at ®ve 10-fold dilutions. After a 48 h incubation period in 5% CO 2 atmosphere and 100% humidity, cells were assayed using the sulforhodamine B assay. In our experiments, between 2000 and 5000 cells/ well were plated and treated with study drug 24 h later. After 4 days in culture, the cells were ®xed in 10% trichloroacetic acid (TCA) and then stained with 0.4% sulforhodamine B (Sigma, MO, USA) in 1% acetic acid. The bound dye was solubilized in 200 ml of 10 mM unbuered Tris solution and the optical density (OD) was determined at a wavelength of 540 nm in an Elisa microplate reader (Bio-Rad Lab. Inc., CA, USA) in quadruplicates. Untreated control wells were assigned a value of 100% and the IC50 was de®ned as the dose required to inhibit the OD to 50% of the control value.
Protein immunoblots
Cells were plated in 100 mm cell culture dishes and grown to 65 ± 75% con¯uence prior to serum starvation and/or drug treatment. Starved cells were incubated for 24 h in serum-free medium. Culture dishes were placed on ice. Subsequently, cells were lysed in TNE (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM Na3OV4, 20 mg/mL aprotinin, 20 mg/mL leupeptin, 5 mM NaF, 1 mM phenylmethylsulfonyl¯uoride (PMSF)). Cell lysates were incubated on ice for 20 min then centrifuged for 4 min at 48C at 14 000 r.p.m. in an Eppendorf centrifuge. Supernatant was transferred to a new microfuge tube and protein concentration was quantitated using Bio-Rad protein assay reagent. For analysis of protein, 100 mg whole cell protein lysate was heated at 1008C in sodium dodecyl sulfate-(SDS) sample buer for 5 min, fractionated by SDS polyacrylamide gel electrophoresis, and transferred to a Bio-Rad 0.45 mm pure nitrocellulose membrane. The membranes were blocked for 1 h with 5% nonfat dry milk, 10 mM Tris-HCL, pH 7.5, 2.5 mM EDTA, pH 8, 50 mM NaCl, 0.1% Tween 20, and 100 mM Na 3 VO 4 (blocking buer) prior to probing with the primary antibodies diluted in blocking buer. After ®ve washes with washing buer (10 mM Tris-HCL, 2.5 mM EDTA, pH 8, 50 mM NaCl, and 0.1% Tween 20), the membranes were exposed to horseradish peroxidase-labeled secondary antibody diluted in blocking buer.
Cell cycle analysis
Forty-eight hours prior to commencement of growth synchronization of representative cell lines, plated cells were trypsinized and replated in 100 mm culture dishes at 40% con¯uence. Twenty-four hours later,¯oating cells were decanted from the plates, fresh medium was added and cells were incubated at 378C overnight. Proliferating cells were then treated with fresh medium, 1 mM AG1478, or 30 ng/ml EGF at 378C for 24 h. Cells were then washed once in PBS, trypsinized, spun down at 1000 r.p.m. for 5 min and resuspended in PBS to yield a 1610 6 cells/ml concentration. Subsequently, 1610 6 cells were aliquoted to a 12675-mm polystyrene centrifuge tube and ®xed in 70% ethanol for a minimum of 2 h on ice. Cells were rehydrated by washing in PBS and then were resuspended in a propidium iodide (25 ug/ml) (Sigma) solution containing RNAse A (500 units/ml) (Sigma) before incubation at room temperature, in the dark, for 30 min. Cell cycle analysis was performed on a BectonDickinson FACScan¯ow cytometer using the SOBR program provided by the manufacturer.
COMPARE analysis and statistical correlation
COMPARE analyses were performed using the previously determined relative expression of the EGF receptor and cerbB2 in the 60 cell lines of the NCI Drug Screen. Pearson correlation coecients, or`r' values, were obtained for each expression pattern, with the cytotoxicity pattern of the tyrosine kinase group of compounds tested in the NCI Drug Screen and stored in its database.
